With the coming conclusion of the MAPP1/MAPP2 Phase 3 clinical trials, MDMA could become widely available as part of an FDA-approved, therapist-supervised prescription treatment for PTSD (post-traumatic stress disorder) as soon as 2023.

Psychedelic drugs are demonstrating therapeutic potential for treating an array of mental conditions such as PTSD, treatment-resistant depression, addiction (e.g. opioids, heroin, cocaine, smoking, alcohol), anorexia, and anxiety.

Society and policymakers are signaling a greater willingness to decriminalize psychedelics for medical uses. Regulators, in turn, are indicating greater openness to therapies that represent a step-up in efficacy over available alternatives.

Some are already concerned that psychedelics are becoming the next “cannabis bubble.” While psychedelics are showing promise, most of the industry players are still at a relatively early stage – suggesting they may be overvalued in this frothy market.

The stage is set for a new, innovative class of prescription treatments that can address persistent mental conditions. The winners among the psychedelic pharma companies will have a foothold in an emerging $100B market.